- Immunome Inc (NASDAQ:IMNM) has announced that its cocktail (IMM-BCP-01) retained activity against the BA.4/5 and BA.2.12.1 subvariants in lab testing.
- IMM-BCP-01 is currently in Phase 1b testing in patients infected with SARS-CoV-2 and in locations where the predominant variants are BA.2.12.1, BA.4, BA.5, and BA.2.
- Related: Immunome Shares Rise After Publishing Positive COVID-19 Antibody Cocktail Data.
- The company expects topline data from Phase 1b study in 2H of 2022.
- IMM-BCP-01 is a three-antibody cocktail, with each antibody having a different mechanism of action.
- “Further, as several existing antibody treatments lose their potency against the Omicron subvariants, IMM-BCP-01 continues to retain activity against these variants in preclinical testing, and we believe our cocktail has the potential to play a significant role in managing the pandemic,” stated Purnanand Sarma, President & CEO.
- Price Action: IMNM shares closed at $3.42 on Tuesday.
Immunome’s COVID-19 Cocktail Retains Neutralizing Activity Against Omicron Subvariants
Immunome Inc (NASDAQ:IMNM) has announced that its cocktail (IMM-BCP-01) retained activity against the BA.4/5 and BA.2.12.1 subvariants in lab testing. IMM-BCP-01…
Related Posts
Judge Bids Farewell To FTX Arena, Leaving The Miami Heat A Home Without A Name
The home of the NBA team the Miami Heat will soon be looking for a new name.
Analyst Ming-Chi Kuo Tweets “Intel Is The Main Loser Of Sapphire Rapids’ Lower-Than-Expected Demand And Microsoft’s Significant Reduction In Sapphire Rapids Server Orders Due To Weak Server Market Demand”
https://twitter.com/mingchikuo/status/1650522019371405317?s=20
Intel is the main loser of Sapphire Rapids' lower-than-expected demand and Microsoft's significant reduction in Sapphire Rapids server
What’s Going On With AMD Stock?
Advanced Micro Devices, Inc. (NASDAQ: AMD) shares are trading higher by 3.3% to $120.69 Tuesday afternoon after Roth MKM initiated coverage on the stock with a Buy rating and announced a $125 price target.